Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
18 April, 2021 21:17 IST
Buy Gland Pharma; target price of Rs 2,700: Motilal Oswal
Source: IRIS | 05 Mar, 2021, 12.54PM
Rating: NAN / 5 stars.
Comments  |  Post Comment

  Gland Pharma (GLAND) is a comprehensively injectable-focused company, with a wide generics portfolio comprising of  a) own/contract development, b) technology transfer, c) an established manufacturing value chain across the range of delivery systems, and d) extensive regulatory capabilities.GLAND is progressing well on building a complex product pipeline, backward integration, and gaining market share in commercialized limited-competition products.

Commenting on the outlook, the brokerage firm Motilal Oswal Retail Research said, "Accordingly, we expect a 25% earnings CAGR over FY20-23. The potential upside in earnings owing to inorganic opportunities funded through cash available on balance sheet is not captured in our estimate.GLAND stands out in the pharma universe with solid track record of developing and commercializing complex products in the injectables space.

Given that injectables have stringent regulatory guidelines compared with other dosages, GLAND is clearly at an advantage on account of its successful compliance.Moreover, it has delivered superior profitability / return ratios with minimal financial leverage. Accordingly, we value GLAND at 29x 12M forward earnings to arrive at target price of Rs 2,700. Initiate with a Buy rating on the stock."

Disclaimer: IRIS has taken due care and caution in compilation of data for its web site. Information has been obtained by IRIS from sources which it considers reliable. However, IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website.


 Post Comment
Name Email
Security Code type    into this box
Nagpur Power & Industries gets nod to increase stake in subsidiary company - 14-Apr-2021 20:29
Hero Motors launches new plant at Hero E Cycle Valley, Punjab - 14-Apr-2021 20:01
Inox Leisure starts commercial operations of Multiplex Cinema Theatre in Bangalore - 14-Apr-2021 19:03
Happiest Minds Technologies in strategic partnership with BeatRoute - 14-Apr-2021 18:48
Venus Remedies enters into partnership with West Pharmaceutical Services - 14-Apr-2021 17:30
Adani Green Energy subsidiary commissions 50 MW solar power plant in UP - 14-Apr-2021 17:02
IDBI Capital maintains Accumulate on TCS with target of Rs 3,530 - 14-Apr-2021 12:31
TCS 4QFY21: Strong FY21 exit rate and deal wins to drive growth in FY22: Motilal Oswal - 14-Apr-2021 09:21
ELGi partners with Italian Red Cross to maintain critical COVID-19 response vehicles - 14-Apr-2021 08:50
IDBI Capital remains positive on IT sector; HCL, Tech Mahindra, Cyient top picks - 12-Apr-2021 19:23
CEMENT: Another round of price hikes; Cement spreads now at the highest since Jun'20: Motilal Oswal - 12-Apr-2021 19:02
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer